Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2002

Leonard Debra G B, Travis Lois B, Addya Kathakali, Dores Graca M, Holowaty Eric J, Bergfeldt Kjell, Malkin David, Kohler Betsy A, Lynch Charles F, Wiklund Tom, Stovall Marilyn, Hall Per, Pukkala Eero, Slater Diana J, Felix Carolyn A

Abstract excerpt

PURPOSE: Although p53 mutations occur in alkylating agent-related leukemias, their frequency and spectrum in leukemias after ovarian cancer have not been addressed. The purpose of this study was to examine p53 mutations in leukemias after ovarian cancer, for which treatment with platinum analogues was widely used. EXPERIMENTAL DESIGN: Adequate leukemic or dysplastic cells were available in 17 of 82 cases of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cisplatin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to DNA, Neoplasm

Share to Leukemia

Share to Myelodysplastic Syndromes

Share to Ovarian Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 12006509

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

p53 mutations in leukemia and myelodysplastic syndrome after ovarian cancer.PMID 12006509Read ↗

Mutations With Loss of Heterozygosity of p53 Are Common in Therapy-Related Myelodysplasia and Acute Myeloid Leukemia After Exposure to Alkylating Agents and Significantly Associated With Deletion or Loss of 5q, a Complex Karyotype, and a Poor PrognosisSemantic proximity Read ↗

Immunohistochemistry for p53 is a useful tool to identify cases of acute myeloid leukemia with myelodysplasia-related changes that are TP53 mutated, have complex karyotype, and have poor prognosis.Semantic proximity Read ↗

TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities.Semantic proximity Read ↗

High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome.Semantic proximity Read ↗

TP53 mutations in myelodysplastic syndrome.Semantic proximity Read ↗

Distinct genetic involvement of the TP53 gene in therapy-related leukemia and myelodysplasia with chromosomal losses of Nos 5 and/or 7 and its possible relationship to replication error phenotypeSemantic proximity Read ↗

Mutations of the p53 tumour suppressor gene in haematologic neoplasms.Semantic proximity Read ↗

Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype.Semantic proximity Read ↗

The p53 gene in pediatric therapy-related leukemia and myelodysplasia.Semantic proximity Read ↗

Increased risk of myelodysplasia and leukaemia after etoposide, cisplatin, and bleomycin for germ-cell tumoursSemantic proximity Read ↗

Detection of p53 gene mutations in human leukemia by PCR-SSCP analysis and direct nucleotide sequencing.Semantic proximity Read ↗

Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.